RxDoctor Payments Data

Andrew Cheng, DPM

Podiatrist · Honolulu, HINPI 1376040162

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,494 of the $2,172 with a category attached, or 68.8%. It is spread thinly across 14 manufacturers, the largest accounting for just 22.2%. Reporting peaked in 2023 at $924 and has fallen 95.0% since, to $46 in 2025.

$2,172in general payments, 2019–2025

Across 32 payments — averaging $67.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$482
  • Elevate Surgical Co$431
  • Arthrex$410
  • Paragon 28, Inc.$250
  • Integra Lifesciences Corporation$120
  • Smith+Nephew$108
  • plus $371 from 8 others

What the payments were for

  • Travel & lodging$65230%
  • Food & beverage$1,49469%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few podiatrist providers in Hawaiito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$107,934
Medicare patients
362
Services billed
1,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CiclopiroxCiclopirox Olamine66$4,407
Colchicine12$378
Doxycycline Hyclate28$310
Meloxicam33$283
Cephalexin18$154

Paid to pharmacies, not to this prescriber.

Other podiatrist in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →